Senhwa Biosciences, Inc. announced that Taiwan Food and Drug Administration has approved its Phase II IND application of Silmitasertib to treat patients with community-acquired pneumonia caused by viral infection.
Inspira Technologies OXY BHN Ltd., a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, announced a significant advancement in its sensor technology by its team of experts.
En el emocionante mundo de los juegos en línea, el juego Aviator se destaca como un fenómeno notable, cautivando a los jugadores a nivel mundial con su singular mezcla de simplicidad. Creado con ingenio, este juego ofrece una experiencia como ninguna otra, fusionando jugabil …
Guía Introductoria de Anna Pérez sobre el Juego Aviator Read More »
Sostenibilidad. Eficiencia energética. Mejores aislamientos. Reducción del consumo y la demanda energéticos. El sector de la construcción y la edificación está viviendo una revolución con el objetivo de conseguir reducir las emisiones de CO2 …
Ferrolan, garantía de materiales de construcción de calidad en Barcelona Read More »
Jemincare announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney and anti-infectious diseases, including 4 approvals from National Medical Products Administration and 2 approvals from the U.S. Food & Drug Administration.
Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs Read More »
LegoChem Biosciences, Inc. announced on December 22 that it has entered into a license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize LCB84, a Trop2 directed antibody drug conjugate (ADC).
LianBio announced that the company has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby Lian has assigned to Janssen LianBio’s exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radioenhancer, in China, South Korea, Singapore and Thailand.
NANOBIOTIX announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize potential first-in-class radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand.
¿Quieres utilizar el poder de ChatGPT sin problemas? ¡No es necesario registrarse ni proporcionar información personal! Descubre cinco formas increíbles de aprovechar ChatGPT al máximo en este artículo. Imagínate con la increíble capaci …
AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition.
